Sinovac Biotech (SVA) Competitors $6.47 0.00 (0.00%) As of 05/22/2026 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SVA vs. GPCR, IDYA, IRON, ARQT, and VERAShould you buy Sinovac Biotech stock or one of its competitors? MarketBeat compares Sinovac Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sinovac Biotech include Structure Therapeutics (GPCR), IDEAYA Biosciences (IDYA), Disc Medicine (IRON), Arcutis Biotherapeutics (ARQT), and Vera Therapeutics (VERA). These companies are all part of the "med - biomed/gene" industry. SVA vs. GPCRSVA vs. IDYASVA vs. IRONSVA vs. ARQTSVA vs. VERAHow does Sinovac Biotech compare to Structure Therapeutics?Sinovac Biotech (NASDAQ:SVA) and Structure Therapeutics (NASDAQ:GPCR) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings. Which has better valuation & earnings, SVA or GPCR? Sinovac Biotech has higher revenue and earnings than Structure Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSinovac Biotech$361.37M1.78$90.90MN/AN/AStructure TherapeuticsN/AN/A-$141.20M-$0.87N/A Do analysts recommend SVA or GPCR? Structure Therapeutics has a consensus price target of $109.25, indicating a potential upside of 178.77%. Given Structure Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Structure Therapeutics is more favorable than Sinovac Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sinovac Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Structure Therapeutics 2 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 3 Strong Buy rating(s) 2.89 Is SVA or GPCR more profitable? Sinovac Biotech's return on equity of 0.00% beat Structure Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Sinovac BiotechN/A N/A N/A Structure Therapeutics N/A -24.91%-23.67% Does the media favor SVA or GPCR? In the previous week, Structure Therapeutics had 2 more articles in the media than Sinovac Biotech. MarketBeat recorded 2 mentions for Structure Therapeutics and 0 mentions for Sinovac Biotech. Structure Therapeutics' average media sentiment score of 0.68 beat Sinovac Biotech's score of 0.00 indicating that Structure Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Sinovac Biotech Neutral Structure Therapeutics Positive Do institutionals & insiders have more ownership in SVA or GPCR? 91.8% of Structure Therapeutics shares are owned by institutional investors. 12.8% of Sinovac Biotech shares are owned by company insiders. Comparatively, 5.6% of Structure Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has more volatility & risk, SVA or GPCR? Sinovac Biotech has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.31, indicating that its share price is 231% less volatile than the broader market. SummaryStructure Therapeutics beats Sinovac Biotech on 7 of the 13 factors compared between the two stocks.How does Sinovac Biotech compare to IDEAYA Biosciences?Sinovac Biotech (NASDAQ:SVA) and IDEAYA Biosciences (NASDAQ:IDYA) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership. Do insiders and institutionals hold more shares of SVA or IDYA? 98.3% of IDEAYA Biosciences shares are owned by institutional investors. 12.8% of Sinovac Biotech shares are owned by insiders. Comparatively, 4.7% of IDEAYA Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts recommend SVA or IDYA? IDEAYA Biosciences has a consensus price target of $50.69, suggesting a potential upside of 74.18%. Given IDEAYA Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe IDEAYA Biosciences is more favorable than Sinovac Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sinovac Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00IDEAYA Biosciences 1 Sell rating(s) 1 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 2.82 Which has better earnings & valuation, SVA or IDYA? Sinovac Biotech has higher revenue and earnings than IDEAYA Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSinovac Biotech$361.37M1.78$90.90MN/AN/AIDEAYA Biosciences$218.71M11.69-$113.70M-$1.60N/A Which has more risk & volatility, SVA or IDYA? Sinovac Biotech has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market. Comparatively, IDEAYA Biosciences has a beta of -0.04, meaning that its share price is 104% less volatile than the broader market. Is SVA or IDYA more profitable? Sinovac Biotech's return on equity of 0.00% beat IDEAYA Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Sinovac BiotechN/A N/A N/A IDEAYA Biosciences N/A -14.24%-13.09% Does the media prefer SVA or IDYA? In the previous week, IDEAYA Biosciences had 2 more articles in the media than Sinovac Biotech. MarketBeat recorded 2 mentions for IDEAYA Biosciences and 0 mentions for Sinovac Biotech. Sinovac Biotech's average media sentiment score of 0.00 beat IDEAYA Biosciences' score of -0.17 indicating that Sinovac Biotech is being referred to more favorably in the media. Company Overall Sentiment Sinovac Biotech Neutral IDEAYA Biosciences Neutral SummarySinovac Biotech beats IDEAYA Biosciences on 7 of the 13 factors compared between the two stocks.How does Sinovac Biotech compare to Disc Medicine?Disc Medicine (NASDAQ:IRON) and Sinovac Biotech (NASDAQ:SVA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation. Is IRON or SVA more profitable? Sinovac Biotech's return on equity of 0.00% beat Disc Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Disc MedicineN/A -36.94% -33.88% Sinovac Biotech N/A N/A N/A Do analysts rate IRON or SVA? Disc Medicine presently has a consensus price target of $105.30, indicating a potential upside of 57.59%. Given Disc Medicine's stronger consensus rating and higher probable upside, equities research analysts plainly believe Disc Medicine is more favorable than Sinovac Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Disc Medicine 1 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.75Sinovac Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders & institutionals believe in IRON or SVA? 83.7% of Disc Medicine shares are owned by institutional investors. 3.8% of Disc Medicine shares are owned by insiders. Comparatively, 12.8% of Sinovac Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media prefer IRON or SVA? In the previous week, Disc Medicine had 6 more articles in the media than Sinovac Biotech. MarketBeat recorded 6 mentions for Disc Medicine and 0 mentions for Sinovac Biotech. Disc Medicine's average media sentiment score of 0.60 beat Sinovac Biotech's score of 0.00 indicating that Disc Medicine is being referred to more favorably in the media. Company Overall Sentiment Disc Medicine Positive Sinovac Biotech Neutral Which has higher valuation & earnings, IRON or SVA? Sinovac Biotech has higher revenue and earnings than Disc Medicine. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDisc MedicineN/AN/A-$212.18M-$6.62N/ASinovac Biotech$361.37M1.78$90.90MN/AN/A Which has more risk & volatility, IRON or SVA? Disc Medicine has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market. Comparatively, Sinovac Biotech has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market. SummaryDisc Medicine beats Sinovac Biotech on 7 of the 12 factors compared between the two stocks.How does Sinovac Biotech compare to Arcutis Biotherapeutics?Arcutis Biotherapeutics (NASDAQ:ARQT) and Sinovac Biotech (NASDAQ:SVA) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations. Is ARQT or SVA more profitable? Sinovac Biotech has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -0.57%. Sinovac Biotech's return on equity of 0.00% beat Arcutis Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Arcutis Biotherapeutics-0.57% -1.41% -0.59% Sinovac Biotech N/A N/A N/A Does the media prefer ARQT or SVA? In the previous week, Arcutis Biotherapeutics' average media sentiment score of 0.00 equaled Sinovac Biotech'saverage media sentiment score. Company Overall Sentiment Arcutis Biotherapeutics Neutral Sinovac Biotech Neutral Which has higher earnings & valuation, ARQT or SVA? Sinovac Biotech has lower revenue, but higher earnings than Arcutis Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcutis Biotherapeutics$376.07M6.94-$16.14M-$0.03N/ASinovac Biotech$361.37M1.78$90.90MN/AN/A Which has more risk and volatility, ARQT or SVA? Arcutis Biotherapeutics has a beta of 1.58, meaning that its share price is 58% more volatile than the broader market. Comparatively, Sinovac Biotech has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market. Do analysts prefer ARQT or SVA? Arcutis Biotherapeutics currently has a consensus target price of $34.00, indicating a potential upside of 62.99%. Given Arcutis Biotherapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Arcutis Biotherapeutics is more favorable than Sinovac Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcutis Biotherapeutics 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.50Sinovac Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryArcutis Biotherapeutics beats Sinovac Biotech on 6 of the 10 factors compared between the two stocks.How does Sinovac Biotech compare to Vera Therapeutics?Vera Therapeutics (NASDAQ:VERA) and Sinovac Biotech (NASDAQ:SVA) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk. Which has higher valuation and earnings, VERA or SVA? Sinovac Biotech has higher revenue and earnings than Vera Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVera TherapeuticsN/AN/A-$299.61M-$5.54N/ASinovac Biotech$361.37M1.78$90.90MN/AN/A Do institutionals & insiders have more ownership in VERA or SVA? 99.2% of Vera Therapeutics shares are owned by institutional investors. 15.9% of Vera Therapeutics shares are owned by company insiders. Comparatively, 12.8% of Sinovac Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is VERA or SVA more profitable? Sinovac Biotech's return on equity of 0.00% beat Vera Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Vera TherapeuticsN/A -74.86% -60.18% Sinovac Biotech N/A N/A N/A Do analysts prefer VERA or SVA? Vera Therapeutics presently has a consensus price target of $79.00, suggesting a potential upside of 132.08%. Given Vera Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Vera Therapeutics is more favorable than Sinovac Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vera Therapeutics 1 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.75Sinovac Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer VERA or SVA? In the previous week, Vera Therapeutics had 1 more articles in the media than Sinovac Biotech. MarketBeat recorded 1 mentions for Vera Therapeutics and 0 mentions for Sinovac Biotech. Vera Therapeutics' average media sentiment score of 1.63 beat Sinovac Biotech's score of 0.00 indicating that Vera Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Vera Therapeutics Very Positive Sinovac Biotech Neutral Which has more risk & volatility, VERA or SVA? Vera Therapeutics has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market. Comparatively, Sinovac Biotech has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market. SummaryVera Therapeutics beats Sinovac Biotech on 8 of the 12 factors compared between the two stocks. Get Sinovac Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for SVA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SVA vs. The Competition ExportMetricSinovac BiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$644.66M$3.37B$6.45B$12.34BDividend YieldN/A2.26%2.76%5.28%P/E RatioN/A18.7421.2225.65Price / Sales1.78323.98553.9286.28Price / Cash3.19125.1743.4956.67Price / Book0.067.0910.377.14Net Income$90.90M$24.45M$3.57B$335.98M7 Day PerformanceN/A5.45%6.01%3.56%1 Month PerformanceN/A2.43%3.52%2.54%1 Year PerformanceN/A62.98%34.13%35.05% Sinovac Biotech Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SVASinovac Biotech0.407 of 5 stars$6.47flatN/AN/A$644.66M$361.37MN/A2,643High Trading VolumeGPCRStructure Therapeutics3.0174 of 5 stars$36.87+2.8%$109.25+196.3%+59.6%$2.54BN/AN/A136IDYAIDEAYA Biosciences3.239 of 5 stars$29.65+4.7%$50.69+71.0%+54.6%$2.49B$218.71MN/A80Positive NewsAnalyst ForecastGap UpIRONDisc Medicine2.3566 of 5 stars$67.03+4.6%$105.30+57.1%+41.1%$2.44BN/AN/A30ARQTArcutis Biotherapeutics2.7127 of 5 stars$20.47+5.0%$34.00+66.1%+49.2%$2.44B$376.07MN/A150 Related Companies and Tools Related Companies GPCR Alternatives IDYA Alternatives IRON Alternatives ARQT Alternatives VERA Alternatives CLDX Alternatives IMNM Alternatives RARE Alternatives KOD Alternatives MLYS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SVA) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sinovac Biotech, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sinovac Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
